Sotrovimab
Based on 6 publication(s) in Google Scholar
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease.
For research use only. We do not sell to patients.
- Purity: 96.80%
- CAS No.: 2423014-07-5
- Molecular Weight:146.463 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Sotrovimab
More-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
RT-PCR
Biological Activity
Human IgG1 kappa
Virus
SARS-CoV-2
Sotrovimab neutralizes both SARS-CoV-2 and SARS-CoV, but does not directly block virus receptor binding[2].
Sotrovimab (100 μg/mL, injected for 200 s, v=30 μL/min) binds efficiently to surface-expressed SARS-CoV-2 S[3].
Sotrovimab (0.3 ng/mL-20 mg/mL; 30 min) neutralizes SARS-CoV-2 pseudo-typed virus in vitro, and also against the Alpha, Beta, Gamma, Delta and Kappa variant viruses with IC50s of 187.2 ng/mL, 71.9 ng/mL, 73.11 ng/mL, 51.3 ng/mL, and 118.64 ng/mL, respectively[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
YP_009724390.1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized SARS-CoV-2/2019-nCoV Spike Protein (RBD, His Tag) can bind Sotrovimab. The EC50 for this effect is 1.47 ng/mL. -
Loaded Sotrovimab on AHC2 biosensor, can bind SARS-CoV-2 S1 Protein (Omicron, B.1.1.529, His, HY-P74445) with an affinity constant of 1.168E-08 M as determined in BLI assay.
Chemical Information
-
CAS No. 2423014-07-5
-
Appearance Liquid
-
Molecular Weight 146.463 kDa
-
Color Colorless to light yellow
-
SMILES
[Sotrovimab]
-
Synonyms
VIR 7831; GSK-4182136
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Emerg Microbes Infect
Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains. [Abstract]2026 Dec;15(1):2686472. PMID: 42324717
Sotrovimab purchased from MedChemExpress. Usage Cited in: Emerg Microbes Infect. 2026 Dec;15(1):2686472. [Abstract]
To evaluate the neutralization profiles of JN.1 and XEC before constructing escape maps, we first compared the following six RBD-targeting antibodies: BD55-1205, 719-14 sIgA, LY-CoV1404, COV2-2130, VIR-7831 (Sotrovimab, 0.001-10 μg/mL), and BRII-196. The results of pseudovirus neutralization detection showed that, except for BD55-1205 and 719-14 sIgA, the other antibodies completely lost their neutralizing activity against JN.1 and XEC variants.
-
Int J Mol Sci
Moloney Murine Leukemia Virus-like Nanoparticles Pseudo-Typed with SARS-CoV-2 RBD for Vaccination Against COVID-19. [Abstract]2025 Jul 4;26(13):6462. PMID: 40650237 -
iScience
Longitudinal analysis of genomic mutations in SARS-CoV-2 isolates from persistent COVID-19 patient. [Abstract]2024 Mar 29;27(5):109597. PMID: 38638575
Sotrovimab purchased from MedChemExpress. Usage Cited in: iScience. 2024 Mar 29;27(5):109597. [Abstract]
Human iPS cell-derived lung organoids were infected with 0.1 MOI of isolated viruses in the presence MOI or absence of remdesivir (RDV) or sotrovimab and cultured for 4 days. Viral RNA copy number in the cell culture supernatant as measured by qPCR. The EC50 of remdesivir or sotrovimab was determined.
-
-
bioRxiv
A cocktail of SARS-CoV-2 spike stem helix domain and receptor binding domain human monoclonal antibodies prevent the emerge of viral escape mutants. [Abstract]2025 Oct 20:2025.10.16.682699. PMID: 41278696
Sotrovimab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 20:2025.10.16.682699. [Abstract]
ARM-B7 mutant also exhibited high-level resistance (NT50 >100 μg/mL, >307-fold increase) to Sotrovimab, a Class III-targeting antibody.
Sotrovimab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2025 Oct 20:2025.10.16.682699. [Abstract]
Fold-change in NT50 of ARM-B7 relative to the parental virus against Casirivimab, SC27, and Sotrovimab NAbs.
-
NAR Mol Med
Mechanism and spectrum of inhibition of viral polymerases by 2'-deoxy-2'-β-fluoro-4'-azidocytidine or azvudine. [Abstract]2025 Aug 11;2(3):ugaf029. PMID: 40900943
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Gupta A, et al; COMET-ICE Investigators. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021 Nov 18;385(21):1941-1950. [Content Brief]
[2]. Case JB, et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat Commun. 2022 Jul 2;13(1):3824. [Content Brief]
[4]. Aweda TA, et al. In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys. Eur J Nucl Med Mol Imaging. 2022 Oct 28:1–12. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)